NCT02685150View on ClinicalTrials.gov

Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease

NACompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Gastroesophageal Reflux DiseaseDyspepsiaBile Reflux
Interventions
DEVICE

Endoscopic Tri-Modal Imaging

Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).

DRUG

Omeprazole

Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.

OTHER

Analysis of gastric juice

Analysis of gastric juice including routine, biochemical and microbiological analysis.

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT02685150 - Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease | Biotech Hunter | Biotech Hunter